See the DrugPatentWatch profile for sarclisa

Sarclisa is a drug used to treat multiple myeloma, a type of blood cancer. It is a human monoclonal antibody that targets a specific protein, called SLAMF7, which is found on the surface of multiple myeloma cells. Sarclisa works by binding to this protein, which helps to activate the immune system and destroy the cancer cells.

Sarclisa was developed by Sanofi and Regeneron Pharmaceuticals and was approved by the US Food and Drug Administration (FDA) in March 2020 for use in combination with the drug pomalidomide and dexamethasone to treat adults with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

According to DrugPatentWatch.com, Sarclisa is currently patent protected in the United States until 2037, with the earliest potential generic entry date being in 2032. The drug is currently available in intravenous (IV) form and is administered by a healthcare professional.

It is important to note that Sarclisa, like all medications, can have side effects. Common side effects include fatigue, diarrhea, upper respiratory tract infection, and pneumonia. It may also cause serious side effects such as infusion reactions, infections, and conditions that can affect the lungs and other organs. Patients should talk to their doctor about the benefits and risks of taking Sarclisa.

In summary, Sarclisa is a drug used to treat multiple myeloma, a type of blood cancer, in combination with pomalidomide and dexamethasone. It was approved by the FDA in March 2020 and is currently patent protected in the United States until 2037. As with any medication, it is important for patients to talk to their doctor about the benefits and risks of taking Sarclisa.

Sources:

* [Sarclisa (isatuximab-irfc) for injection, for intravenous use](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136s000lbl.pdf)
* [Sarclisa (isatuximab-irfc) for injection, for intravenous use](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136s000lbl.pdf)
* [Isatuximab - DrugPatentWatch](https://www.drugpatentwatch.com/drugs/isatuximab)